引言：心血管事件是慢性髓细胞白血病（CML）患者长期并发症之一，而接受酪氨酸激酶抑制剂（TKIs）治疗的患者尤其如此。适当选择TKI和充分管理危险因素可能会减少该人群的心血管并发症。方法：本研究评估了一组CML患者的心血管风险，并进行随访，该组患者在专门的心血管风险咨询中接受了诊断及治疗。为此，我们对2015年至2018年期间在本中心接受TKIs并被转诊到上述咨询的35名患者进行了数据分析。心血管危险因素分别进行分析，并集成到心血管SCORE中，包括诊断时和专门咨询的最后一次就诊时。结果：在诊断时，有60%的患者存在某种类型的危险因素，20%的患者具有高或非常高的危险SCORE，40%的患者处于中等危险范畴，40%的患者属于低危险类别。在随访期间，最常见的心血管不良事件是高血压（在8名患者中诊断出）。66%的患者戒烟，并在95%的患者中控制了血压，50%的患者控制了糖尿病，76%的患者控制了体重，92%的患者控制了血脂异常。5.7%的患者发生血栓事件，并且有相当比例的患者的SCORE有所降低。结论：我们的研究显示，在TKI治疗的CML患者中，通过专门咨询的随访控制心血管危险因素的好处。版权所有2023年 Blanco Sánchez，Gil Manso，Carreño-Tarragona，Paredes Ruiz，González Olmedo，Martínez-López，Díaz Pedroche和Ayala。

Introduction: Cardiovascular events are one of the main long-term complications in patients with chronic myeloid leukemia (CML) receiving treatment with tyrosine kinase inhibitors (TKIs). The proper choice of TKI and the adequate management of risk factors may reduce cardiovascular comorbidity in this population. Methods: This study evaluated the cardiovascular risk of a cohort of patients with CML at diagnosis and after follow-up in a specialized cardiovascular risk consultation. In order to do this, we performed data analysis from 35 patients who received TKIs and were referred to the aforementioned consultation between 2015 and 2018 at our center. Cardiovascular risk factors were analyzed separately, as well as integrated into the cardiovascular SCORE, both at diagnosis and at the last visit to the specialized consultation. Results: At the time of diagnosis, 60% had some type of risk factor, 20% had a high or very high risk SCORE, 40% had an intermediate risk, and 40% belonged to the low risk category. During follow-up, the main cardiovascular adverse event observed was hypertension (diagnosed in 8 patients, 23%). 66% of patients quit smoking, achieving control of blood pressure in 95%, diabetes in 50%, weight in 76%, and dyslipidemia in 92%. 5.7% of patients suffered a thrombotic event and a significant percentage of patients showed a reduction in their SCORE. Conclusion: Our study shows the benefit of controlling cardiovascular risk factors through follow-up in a specialized consultation for patients with CML treated with TKI.Copyright © 2023 Blanco Sánchez, Gil Manso, Carreño-Tarragona, Paredes Ruiz, González Olmedo, Martínez-López, Díaz Pedroche and Ayala.